ESTRO 2024 - Abstract Book

S2373

Clinical - Urology

ESTRO 2024

The baseline IPSS was an average of 15 and increased significantly to an average of 23 at the end of treatment and stabilized at 18 at 12 weeks post-treatment (figure 1), with no difference in both treatment groups.

Table 1. Patients characteristics. Data are expressed as N (%) or median (range).

Characteristic

All patients (N=30)

5-fractions (N=15)

2-fractions (N=15)

Age

73 (61-82)

76 (61-82)

67 (64-79)

Clinical Stage

12

(40)

6

(40)

6

(40)

▪

T1

7

(23.3)

4

(26.7)

5

(33.3)

▪

T2a T2b T2c T3a

7

(23.3)

5

(33.3)

2

(13.3)

▪

1

(3.3)

0

(0)

1

(6.7)

▪

1 (3.3)

0 (0)

1 (6.7)

▪

Gleason's pattern

10

(33.3)

4

(26.7)

6

(40)

▪

3+3 3+4

20 (66.7)

11 (73.3)

9 (60)

▪

Risk group

9

(31)

5

(35.7)

4

(26.7)

▪

Low

19

(65.5)

9

(64.3)

10

(66.7)

▪

Favorable intermediate

1 (3.4)

0 (0)

1 (6.7)

▪

High

Baseline PSA

8.88 (3.6-17)

9.74 (4.9-16.4)

7.4 (3.6-17)

Baseline PSA level

1

(3.3)

0

(0)

1

(6.7)

▪

<4

19

(63.3)

9

(60)

10

(66.7)

▪

4-10

7

(23.3)

4

(26.7)

3

(20)

▪

10-15

3 (10)

2 (13.3)

1 (6.7)

▪

>15

Baseline IPSS

8 (0-17)

6.5 (0-11)

8 (1-17)

Figure 1. IPSS age-adjusted mean values and 95% confidence intervals. *p < 0.05.